** Life sciences firm Avantor's shares AVTR.K fall 4.37% to $20.75 premarket
** Co posts Q4 sales of $1.69 billion, which missed analysts' estimates of $1.71 billion, as per data compiled by LSEG
** Sales hurt by foreign currency and the divestiture of its clinical service business
** Co divested its clinical service business to Audax private equity firm in a deal valued at ~$650 million last year
** Sees 2025 adj profit in the range of $1.02 to $1.10 per share
** Analysts estimate annual profit of $1.10 per share
** Up to last close, stock had fallen 11.93% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.